Document Detail


Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
MedLine Citation:
PMID:  20733134     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrated activity in patients with AML/myelodysplastic syndrome (MDS) with FLT3 mutations.
PATIENTS AND METHODS: Ninety-five patients with AML or MDS with either wild-type (n = 60) or mutated (n = 35) FLT3 were randomly assigned to receive oral midostaurin at 50 or 100 mg twice daily. The drug was discontinued in the absence of response at 2 months, disease progression, or unacceptable toxicity. Response was defined as complete response, partial response (PR), hematologic improvement, or reduction in peripheral blood or bone marrow blasts by ≥ 50% (BR).
RESULTS: The rate of BR for the population in whom efficacy could be assessed (n = 92) was 71% in patients with FLT3-mutant and 42% in patients with FLT3 wild-type. One PR occurred in a patient with FLT3-mutant receiving the 100-mg dose regimen. Both doses were well-tolerated; there were no differences in toxicity or response rate according to the dose of midostaurin.
CONCLUSION: These results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type. The degree of clinical activity observed supports additional studies that combine midostaurin and other agents such as chemotherapy especially in FLT3-mutant AML.
Authors:
Thomas Fischer; Richard M Stone; Daniel J Deangelo; Ilene Galinsky; Elihu Estey; Carlo Lanza; Edward Fox; Gerhard Ehninger; Eric J Feldman; Gary J Schiller; Virginia M Klimek; Stephen D Nimer; D Gary Gilliland; Catherine Dutreix; Alice Huntsman-Labed; Jodi Virkus; Francis J Giles
Related Documents :
19332914 - An analysis of 30 cases of myelodysplastic syndrome.
6950684 - Blastomycosis in immunosuppressed patients.
15468344 - An efficient therapeutic approach to patients with acute promyelocytic leukemia using a...
6385264 - Mitoxantrone as a single agent and in combination chemotherapy in patients with refract...
24625564 - Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial ...
15811244 - Revisiting previously searched locations in visual neglect: role of right parietal and ...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-08-23
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-30     Completed Date:  2010-11-02     Revised Date:  2014-08-24    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4339-45     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*,  enzymology,  genetics*
Male
Mutation
Myelodysplastic Syndromes / drug therapy*,  enzymology,  genetics*
Receptor Protein-Tyrosine Kinases / genetics
Staurosporine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics*
Grant Support
ID/Acronym/Agency:
P01 CA066996/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 120685-11-2/4'-N-benzoylstaurosporine; EC 2.7.10.1/Receptor Protein-Tyrosine Kinases; EC 2.7.10.1/fms-Like Tyrosine Kinase 3; H88EPA0A3N/Staurosporine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk of Arterial Thrombosis Not Increased by Sorafenib or Sunitinib.
Next Document:  Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metas...